DMRA Stock Forecast: Damora Therapeutics, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Damora Therapeutics, Inc. hold a median 12-month price target of $45 — +93.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Damora Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (92): The shares have been drifting up relative to others.
Growth (15): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
DMRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DMRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +93.8% from it.
Of the 16 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | Guggenheim | Maintains | Buy | $60 → $59 |
| 29 Sept 2026 | Wedbush | Reiterates | Outperform | $40 |
| 25 Sept 2026 | Guggenheim | Maintains | Buy | $40 → $60 |
| 30 July 2026 | Wedbush | Maintains | Outperform | $35 → $40 |
| 27 July 2026 | Jefferies | Initiates | Buy | $50 |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $45 |
| 12 June 2026 | Wedbush | Reiterates | Outperform | $35 |
| 11 June 2026 | HC Wainwright & Co. | Initiates | Buy | $45 |
| 28 May 2026 | Wedbush | Initiates | Outperform | — |
| 24 Apr 2026 | RBC Capital | Initiates | Outperform | — |
| 25 Mar 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 17 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 17 Feb 2026 | UBS | Initiates | Buy | — |
| 7 Jan 2026 | Leerink Partners | Initiates | Outperform | — |
| 8 Dec 2025 | Guggenheim | Maintains | Buy | — |
| 1 Dec 2025 | Guggenheim | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DMRA.
This page is one stock. Monday covers all of them.
DMRA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
DMRA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Damora Therapeutics, Inc. returned +33.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DMRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 14.2×
- Price / sales
- —
- Price / book
- 3.9×
- EV / EBITDA
- —
Cheaper than 58% of US stocks
Cheaper than 24% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −115.8%
- Return on assets
- −29.9%
- Dividend yield
- —
Higher than 12% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Damora Therapeutics, Inc. has a market value of $1.4B and an enterprise value of $1.0B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$262.8M.
Free cash flow in the twelve months to 30 June 2026: −$44.5M.
Trailing P/E: 14.2×.
Damora Therapeutics, Inc. employs 7 people.
Data provided by Twelve Data
DMRA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at DMRA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Damora Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about DMRA
What is the DMRA stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Damora Therapeutics, Inc. have a median 12-month price target of $45, with estimates ranging from $40 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DMRA stock a buy right now?
Of the 10 analysts covering Damora Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Damora Therapeutics, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DMRA?
As at 21 Nov 2026, Damora Therapeutics, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).
Will DMRA stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +93.8% from the last close, and Ticker Nerd's factor model ranks Damora Therapeutics, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DMRA stock forecast for 2030?
No analyst covering Damora Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $59 over the next 12 months.
How has DMRA stock performed over the past year?
Damora Therapeutics, Inc. returned +33.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Damora Therapeutics, Inc. do?
Damora Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for hematologic disorders, with an emphasis on mutant calreticulin-driven myeloproliferative neoplasms. Its current pipeline centers on DMR-001, an investigational monoclonal antibody therapy for essential thrombocythemia, alongside DMR-002 and DMR-003, which are designed to broaden coverage across mutCALR-driven disease biology.
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for hematologic disorders, with an emphasis on mutant calreticulin-driven myeloproliferative neoplasms. Its current pipeline centers on DMR-001, an investigational monoclonal antibody therapy for essential thrombocythemia, alongside DMR-002 and DMR-003, which are designed to broaden coverage across mutCALR-driven disease biology. The company also develops GB3226, a small-molecule inhibitor targeting ENL-YEATS and FLT3 for acute myeloid leukemia. Damora Therapeutics concentrates on advancing targeted, disease-modifying therapies for blood cancers and related marrow disorders through a research-driven clinical development model. Founded in 2011 and headquartered in Waltham, Massachusetts, Damora Therapeutics operates in the biopharmaceutical sector as a developer of specialized therapies for patients with significant unmet medical needs.
CEO Ms. Jennifer A. Jarrett M.B.A. · 7 employees · United States · https://www.damoratx.com